Citizen Action of Wisconsin says Mylan, the seller of EpiPen, “contributed thousands of dollars to GOP state legislators in Wisconsin and spent tens of thousands on lobbying to influence the Legislature to help it increase its market in Wisconsin. The legislation is helping Mylan build the monopoly it needs to overcharge for the medication.”
Since 2014, Mylan’s corporate PAC made thousands of dollars in contributions in Wisconsin exclusively to Republican state legislators, focusing on those who serve on the Senate Health Committee, according to CAW based on data compiled by the Wisconsin Democracy Campaign.
Mylan also spent $42,000 between 2013 and 2014 and $24,500 between 2015 and 2016 lobbying in Wisconsin on issues “… affecting the manufacture, distribution, or sale of prescription drugs and medical devices,” as well as on what became 2013 Wisconsin Act 239 and 2015 Wisconsin Act 35 and broadly on “anything relating to generic pharmaceuticals.”
These two measures expanded the scope of users of EpiPens to “recreational and educational camp, college, university, day care facility, youth sports league, amusement park, restaurant, place of employment, and sports arena,” as well as “public, private, or tribal schools.”
Together this expansion is projected to cost the state $77,500 per year for the state to administer.
CAW said “in return for its political donations and lobbying, Mylan has successfully induced state legislators into participating in its marketing scheme to wring windfall profits out of Wisconsin families seeking protection from severe allergic reactions.
The group cited a Wisconsin Public Radio radio report and said Mylan has used state legislation to expand the EpiPen market “in order to position itself to reap a cash windfall from raising prices. With no justification other than profit, Mylan has increased the price of EpiPens by 5 fold since 2007, to the current price of $633 for a two-pack.”
“It is hard to imagine much worse than a family priced out of a medication that could save their child’s life because of the greed of a drug corporation,” said Robert Kraig, executive director of CAW. “Mylan is engaging in grossly unethical business practices with the assistance of state legislators. Under current Wisconsin law, drug corporations like Mylon have the unlimited ability to charge unjustified prices for life-saving medication.
“What Mylan is doing is like selling food or water at a grossly inflated price during a natural disaster. Wisconsin families are trying to pay the inflated price because of the potential life-saving value of the drug.”
CAW said lawmakers should stop promoting the expansion of the EpiPen market and take up state Rep. Debra Kolste’s legislation on prescription drug transparency, which would force Mylan to justify the price of its medications.